Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

BMJ Case Reports

Volumn , Issue , 2009, Pages

  Lebecque, Patrick ^a   Leonard, A ^a   Argaz, M ^a   Godding, Véronique ^a   Pilette, Charles ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896265063     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.07.2008.0379     Document Type: Article

References (5)

1. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppl 3): S225-64. [CrossRef] [Medline] [Web of Science] (Pubitemid 37260463)
2. Marchant JL, Warner JO, Bush A. Rise in total IgE as an indicator of allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 1994; 49: 1002-5. [Abstract/FREE Full text] (Pubitemid 24315993)
3. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101: 1483-92. [CrossRef] [Medline] [Web of Science] (Pubitemid 46850589)
4. van der Ent KC, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62: 276-7. [Abstract/FREE Full text] (Pubitemid 46579813)
5. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediat Pulmonol 2008; 43: 607-10. [CrossRef ] (Pubitemid 351813015)